TNFRSF8 and peripheral T-cell lymphoma, not otherwise specified: In the United States, brentuximab vedotin (BV) in combination with chemotherapy is approved for adults with previously untreated stage III/IV classical Hodgkin lymphoma (cHL) and for adults with previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL) [1].